☆ 4.4 Article

High recurrence rate of eczema herpeticum in moderate/severe atopic dermatitis -TREATgermany registry analysis

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Dermatology

JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

Benjamin Klein et al.

Summary: JAK inhibitors have shown promising results in treating various chronic inflammatory skin diseases through their ability to target proinflammatory cytokines released via the JAK-STAT pathway. Recent approvals of JAK inhibitors like Baricitinib, Upadacitinib, and Abrocitinib offer new systemic therapeutic options for moderate to severe atopic dermatitis patients. While these small molecules have demonstrated effectiveness, potential side effects and necessary laboratory examinations should be carefully considered.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)

添加到收藏夹

Article Dermatology

Perception of the coronavirus pandemic by patients with atopic dermatitis - Results from the TREATgermany registry

Claudia Helmert et al.

Summary: Among patients with atopic dermatitis, the coronavirus pandemic was considered a life-changing event, with male and younger patients experiencing higher personal burdens compared to females and older patients. Regardless of disease severity, patients with higher quality of life impairments and greater disease severity perceived the burden of the coronavirus pandemic as less severe.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)

添加到收藏夹

Review Dermatology

The role of the skin microbiome in atopic dermatitis - correlations and consequences

Regina Foelster-Holst

Summary: The physical barrier function of the skin is supported by the (epi-)dermal immune system and the skin's own microbiome. Atopic dermatitis is characterized by changes in the skin microbiome, with Staphylococcus aureus playing a dominant role. The bacteria further weaken the compromised skin barrier function and exacerbate inflammation in patients with atopic dermatitis. However, understanding dermal dysbiosis offers new treatment options for the disease.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)

添加到收藏夹

Review Allergy

The HOME Core outcome set for clinical trials of atopic dermatitis

Hywel C. Williams et al.

Summary: Core outcome sets are crucial in atopic dermatitis research, providing a standardized approach to measuring outcomes and improving clinical practice.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

Thomas Bieber

Summary: Recent advances in understanding of the complex phenotype and mechanisms underlying atopic dermatitis (AD) have revealed multiple new potential targets for pharmacological intervention. There are now more than 70 new compounds in development, in addition to regulatory approval for several inhibitors in Europe. The potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease is highlighted.

NATURE REVIEWS DRUG DISCOVERY (2022)

添加到收藏夹

Article Dermatology

An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis

T. Werfel et al.

Summary: This study examined the occurrence of herpes simplex infections in adult patients with AD receiving baricitinib treatment. The study found that herpes simplex was common, eczema herpeticum occurred less frequently, and herpes zoster events were rare and not dose-dependent. Most herpes simplex events were mild or moderate, and rarely led to permanent discontinuation.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Article Dermatology

Update Systemic treatment of atopic dermatitis of the S2k-guideline on atopic dermatitis

Thomas Werfel et al.

Summary: This guideline is an update from August 2020 of the S2k-guideline Atopic dermatitis published in 2015, focusing on the latest scientific data and developments in the field of systemic therapy for atopic dermatitis, especially with the approval of dupilumab. The guideline provides recommended suggestions for systemic treatment of atopic dermatitis and recommends standardized documentation of the indication for systemic therapy.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2021)

添加到收藏夹

Article Dermatology

Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needs

Matthias Augustin et al.

Summary: In Germany, skin diseases are mainly treated in dermatological hospitals, with a high number of inpatient treatment cases in 2018. The most common cases include epithelial skin cancer and melanoma. The average length of stay is 5.69 days, and there is expected to be continued high demand for inpatient care for skin diseases in the future.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2021)

添加到收藏夹

Article Allergy

Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum

Lianghua Bin et al.

Summary: This study identified damaging genetic variants associated with HSV infection in atopic dermatitis patients with a history of recurrent eczema herpeticum. Genes SIDT2 and RBBP8NL were found to play crucial roles in keratinocyte response to HSV-1 infection and regulation of keratinocyte differentiation.

ALLERGY (2021)

添加到收藏夹

Review Allergy

Eczema herpeticum in atopic dermatitis

Stephan Traidl et al.

Summary: Atopic dermatitis (AD) is a common inflammatory skin disease that can lead to severe HSV infection in some patients, known as eczema herpeticum (EH). The predisposition to EH involves genetic aberrations, immunological changes, and environmental influences, which require further research to fully understand.

ALLERGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich et al.

Summary: This study evaluated the efficacy and safety of upadacitinib in combination with topical corticosteroids for moderate-to-severe atopic dermatitis, showing that upadacitinib was more effective and well tolerated compared to placebo.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials

Emma Guttman-Yassky et al.

Summary: The clinical trials demonstrated that Upadacitinib may be an effective treatment option for moderate-to-severe atopic dermatitis, with a significant improvement in symptoms for most patients within 16 weeks, and both dosages were well tolerated.

LANCET (2021)

添加到收藏夹

Review Allergy

Status report on the atopic dermatitis registry TREATgermany

D. Siegels et al.

Summary: The TREATgermany registry in Germany collects clinical data from patients with moderate-to-severe atopic dermatitis, with 59 participation centers as of May 2021. The majority of patients in the registry are treated with corticosteroids and biologics, according to the latest data.

ALLERGOLOGIE (2021)

添加到收藏夹

Article Dermatology

Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients

M. Seegraeber et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Article Dermatology

Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany

A. Heratizadeh et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Eric L Simpson et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Atopic dermatitis

Sinéad M Langan et al.

LANCET (2020)

添加到收藏夹

Article Dermatology

TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries

L. A. A. Gerbens et al.

BRITISH JOURNAL OF DERMATOLOGY (2019)

添加到收藏夹

Article Dermatology

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

Lawrence F. Eichenfield et al.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)

添加到收藏夹

Letter Allergy

Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses

Stephan Traidl et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)

添加到收藏夹

Article Dermatology

Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials

Patrick Fleming et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

添加到收藏夹

Article Allergy

Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum

Lianghua Bin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

添加到收藏夹

Article Allergy

The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials

Jochen Schmitt et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

添加到收藏夹

Article Allergy

Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting

Jochen Schmitt et al.

ALLERGY (2012)

添加到收藏夹

Article Allergy

Staphylococcus aureus α-toxin modulates skin host response to viral infection

Lianghua Bin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)

添加到收藏夹

Article Dermatology

Genetic Variants in Interferon Regulatory Factor 2 (IRF2) Are Associated with Atopic Dermatitis and Eczema Herpeticum

Pei-Song Gao et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)

添加到收藏夹

Letter Allergy

Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum

Pei-Song Gao et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)

添加到收藏夹

Article Allergy

Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum

Pei-Song Gao et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)

添加到收藏夹

Article Allergy

Phenotype of atopic dermatitis subjects with a history of eczema herpeticum

Lisa A. Beck et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)

添加到收藏夹

Letter Dermatology

Risk factors of atopic dermatitis patients for eczema Herpeticum

Wenming M. Peng et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)

添加到收藏夹

Article Allergy

Viral infections in atopic dermatitis: Pathogenic aspects and clinical management

A Wollenberg et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)

添加到收藏夹

Article Dermatology

Predisposing factors and clinical features of eczema herpeticum: A retrospective analysis of 100 cases

A Wollenberg et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)

添加到收藏夹

Article Allergy

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

S Reitamo et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2002)

添加到收藏夹

Article Dermatology

Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment

J Lubbe et al.

DERMATOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.